Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)

NCT02866916 | Withdrawn Phase 1 DMC

• 1 other identifier: 16GENH01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single site, open-label, non-randomized, dose escalation phase I study designed to evaluate the safety, the tolerability and the Recommended Phase II Dose (RP2D) of SXL01, a synthetic small interfering ribonucleic acid (RNA) targeting the androgen receptor messenger RNA (mRNA), in patients with metastatic castration-resistant prostate cancer. A standard method "3+3" will be used for dose escalation. A maximum of 30 patients will complete the dose-escalation phase of the study; 12 additional patients will be included at the RP2D in the expansion phase.

Conditions

Prostatic Cancer, Castration-Resistant

Outcome Measures

Primary Outcomes (3)

• Incidence rate of Dose Limiting Toxicities (DLT) during the first cycle of treatment with SXL01.

  25 months

• Characteristics of Dose Limiting Toxicities (DLT) during the first cycle of treatment with SXL01.

  25 months

• Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Tolerability and safety will be assessed through recording of adverse events using National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) toxicity classification, monitoring biological parameters and vital signs measurement.

  33 months

Secondary Outcomes (3)

• Preliminary efficacy endpoint : rate of patients presenting Prostate Specific Antigen (PSA) progression defined using Prostate Cancer Clinical Trial Working Group 3 (PCWG3)

  33 months

• Preliminary efficacy endpoint : rate of patients presenting clinical or radiological progression using Response Evaluation Criteria in Solid Tumours (RECIST) V1.1 as defined by PCWG3.

  33 months

• Pharmacokinetics - SXL01 plasma concentration

  Cycle 1: pre-dose (T0) then 0.5, 3, 6, 24 hours post dose on day 1 ; T0 on days 4, 8, 15, 22. Subsequent cycles : before administration on day 1 (CXD1). The day of treatment discontinuation (CXDX) : 0.5, 1, 2, 24 hours post-dose.

Study Arms (1)

Dose escalation

EXPERIMENTAL

The standard method "3+3" will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01. Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent. Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase.

Drug: SXL01

Interventions

SXL01 DRUG

Treatment will be administered continuously over 24h through the subcutaneous route.

Dose escalation

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males age 18-80 years.
• ECOG performance status 0 - 1.
• Life expectancy of more than 3 months.
• Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small cell feature.
• Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy.
• Detectable metastases by bone scan, CT scan or MRI.
• Surgically or medically castrated, with testosterone levels of \< 50 ng/dL (\< 2.0 nM). If the patient is being treated with LHRH agonists (patient who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study.
• Documented prostate cancer progression as assessed by the investigator with one of the following:
• PSA progression defined by a minimum of two raising PSA levels with an interval of \>1 week between each determination. The PSA values at the screening visit must be ≥ 1 µg/l (1 ng/mL).
• Radiographic progression of soft tissue disease by modified RECIST criteria 1.1 or of bone metastasis with two or more documented new bone lesions on a bone scan with or without PSA progression.
• Adequate hepatic, renal, and hematologic function: AST/ALT ≤ 2.5 X ULN; Normal bilirubin or ≤ 1.5 ULN in case of Gilbert's syndrome; Serum creatinine CL\> 60 mL/min by the Cockcroft-Gault formula; Hemoglobin ≥ 10 g/dL; Absolute neutrophil count ≥ 1500/mm3, Platelet count ≥ 100,000/mm3.
• If sexually active, willing to use barrier contraception during the treatment phase of the protocol.
• Written informed consent and any locally required authorization (e.g., Social security for France (Health Insurance)) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.
• Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

You may not qualify if:

• BMI ≥ 30.
• Evidence of brain metastasis.
• Patient seropositive for HIV and/or hepatitis B antigen positive and/or Hepatitis C antibody.
• Patient with history of autoimmune disease with the exception of vitiligo, psoriasis and controlled diabetes.
• Active suspected or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, irritable bowel syndrome, Wegener's granulomatosis and Hashimoto's thyroiditis).
• Patient with history of another malignancy, except for the following: skin cancers (melanoma excluded), previously treated cancer with no sign of disease for at least 3 years.
• Patient with concurrent infection or concurrent chronic or acute illness such as pulmonary (asthma or COPD), cardiac (NYHA class III or IV) or hepatic disease, or other illness considered by the principal investigator to constitute an unwarranted high risk for investigational drug administration will be excluded.
• Patient who has got a medical condition contraindicated for subcutaneous administration.
• Chronic systemic corticosteroid use within 4 weeks of the first administration of SXL01 (more than 2 weeks for a dose \> 0.5 mg/kg of prednisolone).
• Treatment with any hormonal therapy or androgen antagonist, including flutamide, bicalutamide, nilutamide, ketoconazole, diethylstilbestrol, Abiraterone, or enzalutamide, within 4 weeks of the first administration with the exception of GnRH agonists.
• Patients requiring a continuous curative anti-coagulant treatment.
• Planned to initiate any other anti-tumor therapies during the study.
• Radiation therapy or surgery within 4 weeks of the first administration of SXL01.
• Mental impairment (psychiatric illness/social situations) that may compromise the ability of the patient to give informed consent and comply with the requirements of the study.
• Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Sponsors & Collaborators

• Institut Claudius Regaud: lead

Study Sites (1)

Institut Claudius Regaud

Toulouse, 31059, France

Location

MeSH Terms

Conditions

Prostatic Neoplasms, Castration-Resistant

Condition Hierarchy (Ancestors)

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Jean-Pierre DELORD, MD, PhD

  IUCT-O

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 8, 2016
• First Posted: August 15, 2016
• Study Start: September 1, 2017
• Primary Completion: June 1, 2020
• Study Completion: June 1, 2020
• Last Updated: January 20, 2021

Record last verified: 2016-11

Locations

FR (1)